At 12 months post-GLP-1RA-initiation, the concomitant use of anti-diabetes agents was as follows: metformin, SGLT2 inhibitors, insulin, sulfonylureas, α-glucosidase inhibitors, glinides, and thiazolidinediones (Table 2). Here, SLC5A2 is linked to diabetes mellitus.